{"id":"W4296532403","doi":"10.1016/s2152-2650(22)01303-9","title":"AML-484 First Results of a Phase II Study (STIMULUS-AML1) Investigating Sabatolimab + Azacitidine + Venetoclax in Patients With Newly Diagnosed Acute Myeloid Leukemia (ND AML)","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University of British Columbia; McGill University; University of Toronto; Jewish General Hospital","funders":"","keywords":"Venetoclax; Medicine; Azacitidine; Cohort; Internal medicine; Neutropenia; Myeloid leukemia; Myeloid; Myelodysplastic syndromes; Oncology; Hypomethylating agent; Tolerability; Leukemia; Gastroenterology; Chemotherapy; Adverse effect; Chronic lymphocytic leukemia; Bone marrow","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.003800297,0.001241051,0.003144443,0.001014201,0.001110884,0.00009099455,0.001675273,0.0005737963,0.000270303],"category_scores_gemma":[0.005186063,0.001148151,0.000640196,0.003519405,0.001406759,0.0004986323,0.002500624,0.002477221,0.0000767876],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.01591009,"about_ca_system_score_gemma":0.01217012,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002533589,"about_ca_topic_score_gemma":0.0004719463,"domain_scores_codex":[0.9859141,0.001406568,0.004784056,0.002646332,0.003174841,0.002074135],"domain_scores_gemma":[0.9899096,0.003242266,0.001743885,0.002812,0.0008027822,0.001489468],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.07002507,0.01450627,0.5761768,0.0004660564,0.002473325,0.007676278,0.006382441,0.005018782,0.0009160416,0.00007522316,0.01928305,0.2970007],"study_design_scores_gemma":[0.1795184,0.03622205,0.7657936,0.0005373565,0.0006841408,0.0001354083,0.001343711,0.009039472,0.0005439062,0.00007048151,0.00500652,0.001105018],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9915451,0.0001924419,0.00001546577,0.0007030009,0.0004506982,0.005101601,0.0007724203,0.0003020862,0.0009171493],"genre_scores_gemma":[0.9931107,0.00008536974,0.001972904,0.001241442,0.000473718,0.0008756201,0.001176545,0.0003204418,0.0007433086],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2958957,"threshold_uncertainty_score":0.9998241,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02956475525237945,"score_gpt":0.3289052591413446,"score_spread":0.2993405038889651,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}